Yale Medicine pediatrician weighs in on Pfizer’s new vaccine trial data for children ages 5 to 11

NEW HAVEN, Conn. (WTNH) — Today a major step has been taken in the fight against COVID-19. Younger children could soon receive protection from the virus as Pfizer submits vaccine trial data to the FDA for ages five to 11.

“They shared that the evidence looks very strong in more than 2,000 children,” says Yale Medicine pediatrician Leslie Sude.

“The vaccine showed a favorable safety profile and elicited robust neutralizing antibody responses using a two-dose regimen of 10 µg doses,” Pfizer said in a press release.

The vaccine dose for children ages 5 to 11 is one-third of the dose given to children 12 years of age and older and adults.

“A dose tailored for that age group of ten micrograms will provide robust immunity and a very high safety profile for the use of this vaccine against the coronavirus,” said Dr. sude.

The CEO of Pfizer says the company is ready to enter the next production phase.

“If they approve, we will be done with our production to deliver this new formulation of the vaccine…” said Albert Bourla, CEO of Pfizer.

dr. Sude said parents of her young patients have been eagerly awaiting this information about the vaccine trial. She wants them to prepare to make an informed decision before the actual vaccine is released.

“We want people to come in and talk to us. Make the decision now so that our families will be ready when the vaccine is ready.”

dr. Sude also wants to disprove what some parents think when they hear the term “emergency use authorization.”

“However, somehow in their mind that translates into an experiment, the technology for these vaccines has been around for decades and in some aspects of the technology over 25 years.”

She says the next subset of children in COVID vaccine trials right now are ages two to five, but she hasn’t seen any preliminary data on them yet.

Comments are closed.